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Biochemical and cell culture studies have characterized the myocyte enhancer factor 2 (MEF2) transcriptional regulatory proteins as
obligatory partners for the myogenic regulatory factors (MRFs) in the differentiation of myogenic cells in culture. However, the role of MEF2
activation in somitic myogenesis has not been fully characterized. Here, we report a critical interaction between the p38 mitogen-activated
protein kinase (p38 MAPK) and MEF2 in the developing somite myotome. We document expression of MEF2A and p38 MAPK proteins in
the somite of 9.5 dpc mouse embryos concurrent with Myf 5 protein expression. We also observed that abrogation of p38 MAPK signaling
blocks MEF2 activation using a MEF2 transgenic Fsensor_ mouse. Inhibition of p38 MAPK signaling concurrently inhibited myogenic
differentiation in somite cultures and in embryos in vivo using transplacental injection of a p38 inhibitor (SB203580). Finally, we document
that commitment to the myogenic lineage is not appreciably affected by p38 MAPK inhibition since the activation of an early marker of
myogenic commitment (Myf 5) occurs normally when p38 MAPK signaling is inhibited. Thus, we present novel evidence indicating a crucial
role for p38 MAPK signaling to the MEF2 transcriptional regulators during early mammalian somite development and myotome formation.
D 2005 Elsevier Inc. All rights reserved.Keywords: p38 MAPK; MEF2; Muscle regulatory factorsIntroduction
Orchestration of skeletal muscle differentiation and
higher-order architecture is a fundamental and early step
in the development of metazoan species (Cossu et al.,
1996b; Tajbakhsh and Cossu, 1997). The inception of
skeletal myogenesis occurs shortly after gastrulation and
continues for an extended period of embryogenesis (Christ
and Ordahl, 1995; Wachtler and Christ, 1992). The skeletal
muscle of the vertebrate body plan is primarily derived from
somites, blocks of paraxial mesoderm that progressively0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: jmcderm@yorku.ca (J.C. McDermott).segment in a cranial to caudal direction during embryonic
development (Christ and Ordahl, 1995; Ordahl and Le
Douarin, 1992; Venters et al., 1999). In the newly formed
somite, the cells in the dorsal region (dermomyotome)
commit to the myogenic and dermal lineages while the cells
of the ventral region (sclerotome) give rise to the cartilage
and bone (Christ and Ordahl, 1995; Ordahl and Le Douarin,
1992). This determination is orchestrated by signaling from
axial structures, surface ectoderm and lateral plate meso-
derm (Buffinger and Stockdale, 1994; Cossu et al., 1996a,
2000).
Molecular analysis of somitic myogenesis has docu-
mented the key role played by the muscle regulatory
factors (MRF) family, comprised of MyoD, Myf 5,
myogenin, and MRF4, in the commitment and differ-283 (2005) 171 – 179
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Kablar et al., 1997; Kassar-Duchossoy et al., 2004; Ott et
al., 1991; Rudnicki et al., 1993; Tajbakhsh et al., 1996b).
Biochemical and cell culture studies have also charac-
terized the myocyte enhancer factor 2 (MEF2) transcrip-
tional regulatory proteins as obligatory partners for the
MRFs in the differentiation of cultured myogenic cells but
the role of p38–MEF2 signaling in the somite myotome
has not, thus far, been characterized. Interestingly, deletion
of the MEF2 site in the myogenin promoter has been
shown to modulate its normal pattern of activation in the
somite, suggesting a requirement for MEF2 activity in the
somitic activation of myogenin expression (Cheng et al.,
1993; Yee and Rigby, 1993). In this regard, while the loss
of function analysis of the MRFs by gene targeting has
been fruitful in building a genetic regulatory circuit for
embryonic myogenesis (Hasty et al., 1993; Kassar-
Duchossoy et al., 2004; Rudnicki et al., 1993), the loss
of function analysis of MEF2 has not elucidated the role
of MEF2 in the somite (Bi et al., 1999; Lin et al., 1997;
Naya et al., 2002). The main reason being that the MEF2
factors have pleiotropic roles in neurons, T cells, cardiac,
skeletal and smooth muscle (Bour et al., 1995; Firulli et
al., 1996; Lilly et al., 1995; Lin et al., 1997; Mao et al.,
1999; Olson et al., 1995; Ornatsky et al., 1997; Youn et
al., 1999), and possibly other tissues, unlike the highly
tissue-specific expression and activity of the MRFs. Thus,
the loss of function of the MEF2 genes to date (Bi et al.,
1999; Lin et al., 1997; Naya et al., 2002) has generated
diverse and complex phenotypes that have not allowed a
clear insight into the exact role for MEF2 activity in the
developing somite. However, analysis of a MEF2 Fsensor
mouse_ comprising of an artificial reporter gene contain-
ing MEF2 sites driving the LacZ gene indicates robust
MEF2 activity during early embryonic development in the
somites suggesting a potential role (Naya et al., 1999).
One key aspect of the control of MEF2 activity that
has emerged is an acute responsiveness to cellular
signaling pathways as exemplified by the exquisite control
exerted over these factors by signaling pathways (Cox et
al., 2000; McKinsey et al., 2002). In particular, the p38
mitogen-activated protein kinase cascade (p38 MAPK)
and ERK5/BMK1 kinases are potent regulators of MEF2
function (Cox et al., 2003; Han and Molkentin, 2000;
Kato et al., 1997; Ornatsky et al., 1999; Puri et al., 2000;
Wu et al., 2000; Yang et al., 1998, 1999; Zhao et al.,
1999). In fact, previous work has shown that the MEF2A
and MEF2C proteins are virtually transcriptionally inert
without p38 MAPK signaling pathway input (Ornatsky et
al., 1999). Also, MEF2 factors have been shown to be
activated by p38 MAPK in cardiac myocytes and this
activation has been implicated in cardiac hypertrophy in
experimental model systems (Wang et al., 1998; Zechner
et al., 1997).Therefore, in considering the role of MEF2
activity in the somite, a crucial determinant may be the
p38 MAPK signaling pathway input.Four different p38 MAPK isoforms have been charac-
terized (a, h, g, y) although MEF2 is only efficiently
targeted by the a, h isoforms (Zhao et al., 1999). p38
MAPKs are activated by dual phosphorylation of a TGY
peptide motif by the MKK6/MKK3 MAP kinase kinases
and also by transforming growth factor-h-activated kinase 1
binding protein 1 (TAB1) (Ge et al., 2002; Nebreda and
Porras, 2000; Ono and Han, 2000; Pearson et al., 2001;
Whitmarsh and Davis, 2000).
In this report, we have addressed the role of the p38
MAPK–MEF2 signaling pathway during somitic myo-
genesis. These studies document that MEF2 activity in the
developing vertebrate myotome, but not in the heart, is
extinguished by abrogation of p38 MAPK signaling and that
the loss of p38 MAPK signaling blocks myotomal myogenic
differentiation.Materials and methods
Cell cultures
Cells were cultured from transgenic mouse embryos at
the 20–25 somite stage at 9.5 days postcoitum (p.c.) as
described previously (Cusella-De Angelis et al., 1992;
Vivarelli et al., 1988). Briefly, embryonic tissue was
dissociated by gentle pipetting in a Ca2+ Mg2+ free PBS
to obtain a single cell suspension. Cells were collected by
centrifugation. Cells were inoculated at an initial density of
3  105 cells/ml DME supplemented with 10% fetal bovine
serum. In experiments in which different regions of the
somites were used, the trunk, comprising of axial structures,
including notochord, neural tube, and paraxial mesoderm,
was dissected into separate blocks of 5 somites (namely,
I–V, VI–X, and XI–XV, where somite I is the most recently
formed caudal somite) (Cusella-De Angelis et al., 1992). The
unsegmented paraxial mesoderm (upm) was also dissected in
some cases. Where indicated, the neural tube was separated
from the somites by treatment with 0.25% collagenase/0.1%
dispase for 5 min at 30-C, washed and then gently pipetted
through a siliconized capillary to obtain a cell free
suspension. Approximately 80% of cells were viable at the
time of plating, as indicated by trypan blue exclusion. For
analysis of monolayer and explant cultures, cells were fixed
in 2% paraformaldehyde/0.2%glutaraldehyde in PBS on ice
for 10 min. Followed by washing twice in PBS for 10 min.
The cells were subsequently incubated in X gal staining
solution (5 mM ferrocyanide; 5 mM ferricyanide; 2 mM
MgCl2; 1 mg/ml X gal) for 2–3 h at 37-C.
Whole embryo incubation
The MEF2-LacZ transgenic mouse embryos were dis-
sected at 9.5 dpc from timed pregnant female mice and
cultured in a 24-well plate with 1 ml DMEM/10% FBS
containing 10 AM p38 inhibitor at 37-C for 72 h. After
L. de Angelis et al. / Developmental Biology 283 (2005) 171–179 173incubation, the embryos were fixed with 2% paraformalde-
hyde/0.2 glutaraldehyde for 1 h. The embryos were rinsed
twice with PBS, and then immersed in X gal staining
solution (5 mM ferrocyanide; 5 mM ferricyanide; 2 mM
MgCl2; 1 mg/ml X gal) at 37-C for 2–3 h.
Transplacental injection
Placental injection was carried out as we have previously
described (Borello et al., 1999). Briefly, 5 Al of SB203580 or
the control (SB203470) was injected into the maternal side
of the placenta through the uterine wall using a syringe with
a 30-Ga 1/2 needle. Concentrations used were approximated
to result in a final concentration of 15–30 AM in the
placenta based on approximations of the intrapacental fluid
volume. Mice were anesthetized by intramuscular injection
of a 3:1 mixture of Ketamine/Xylazine (Parke-Davies/
Bayer) in a volume of 1 Al/g of body weight. One uterine
horn of the embryos (at E8.5 dpc) was injected. Mice were
sacrificed 48 h post-injection and embryos were collected
and processed for X gal staining (embryos were incubated in
X gal solution, as above, for 2–3 h).
Trangenic mouse lines
The MLC3F-nLacZ transgenic mouse contains 2 kb of
the mouse fast myosin light chain 3 (MLC3F) upstream
sequence, including the promoter, with 1 kb of sequence
downstream of the transcription initiation site and a 3V
muscle specific enhancer from this gene, fused to an nLacZ
simian virus 40 polyadenylation sequence (Kelly et al.,
1995). Heterozygous transgenic males were crossed with
CD1 outbred female mice. Embryos were dated by taking
0.5 dpc as the day of the vaginal plug. The MEF2 Fsensor_
mouse characterized by Naya et al. (1999) contains two
copies of the MEF2 site from the Desmin gene upstream of
nLacZ. The Myf 5 reporter mouse contains a nuclear
localized LacZ gene (nLacZ) Fknock in_ at the Myf 5 locus
(Tajbakhsh et al., 1996a).
Immunocytochemistry
Embryos were fixed in 4% paraformaldehyde in PBS,
dehydrated through a series of sucrose solutions (12, 18, and
30%), sectioned in the cryostat and mounted on gelatin-
coated slides. The slides were washed in 1% BSA in PBS for
30 min. Sections were incubated overnight at room temper-
ature in a humidified chamber with the primary antibodies
(polyclonals at 1:500 and monoclonals at 1:10 unless
otherwise stated). After the incubation, sections were washed
three times with 1% BSA in PBS. And then incubated with
fluorescein-conjugated goat anti-rabbit Ig and with a rhod-
amine-conjugated goat anti-mouse at 1:30 dilution for 1 h at
RT. Slides were mounted in PBS at pH 8.0 supplemented
with 75% glycerol and observed under an epifluorescence
microscope (Carl Zeiss, Oberkochen, Germany). For co-localization experiments of MEF2A or Myf 5 with MEF2
lacZ, the somite cultures were fixed in ice-cold paraformal-
dehyde for 30 min. After three washes in cold PBS for 10
min, the cells were incubated with polyclonal anti Myf 5 or
myogenin (1:50 dilution) for 1 h at 37 C. After three 10-min
washes in PBS, the cells were incubated for 2 h at room
temperature with fluoroscein (FITC)-conjugated anti-rabbit
IgG (1:50 dilution). Cells were washed as before and then
incubated with X gal solution (5 mM ferrocyanide, 5 mM
ferricyanide, 2 mM MgCl2, 1 mg/ml X gal in dimethylfor-
mamide) for 1 h at 37-C and examined using fluorescence
microsocopy. Antibodies used were: anti-myosin heavy
chain monoclonal (MF20) (Baeder et al., 1982); MEF2A,
B, C, D rabbit polyclonal antibodies (MEF2A—two MEF2A
antibodies were used. One from R. Prywes, Columbia
University, the other was raised in our laboratory. MEF2B
and D from R. Prywes. MEF2C—McDermott et al., 1993);
myf5 (Santa Cruz); myogenin (Santa Cruz).
Western blot analysis
After transfer, nitrocellulose was washed with TBS, then
incubated in blocking buffer [TBS/T (0.2 M Tris base, 1.36
MNaCl, 1.0% Tween-20)] with 5%w/v nonfat dry milk. The
membrane was then washed 3 times with wash buffer (1 
TBS, 0.1% Tween-20) and then incubated with the appro-
priate antibody (Phospho-ATF-2 antibody for kinase assay,
and p38 MAP Kinase Antibody for p38 Western) overnight
at 4-C. Membranes were then washed 3 times with wash
buffer and incubated with HRP-conjugated secondary anti-
body for 1 h at room temperature. The membrane wash then
washed 3 times in wash buffer. Protein was detected using
LumiGLO chemiluminesence.
Immunoprecipitation kinase assays
A kinase assay was performed using the p38 MAP
Kinase Assay Kit (Cell Signaling). In brief, tissue was lysed
in cell lysis buffer [20 mM Tris (pH 7.5), 150 mM NaCl, 1
mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium
pyrophosphate, 1 mM h-Glycerolphosphate, 1 mM
Na3VO4, 1 Ag/ml Leupeptin]. For immunoprecipitations,
20 Al of immobilized phospho p38 antibody was added to
140 Ag (protein concentration) of lysate from each sample
tissue and incubated overnight at 4-C. After centrifugation,
pellet was washed twice with lysis buffer, and then twice
with kinase buffer [25 mM Tris (pH 7.5), 5 mM h-
Glycerolphosphate, 2 mM DTT, 0.1 mM Na3VO4, 10 mM
MgCl2]. Pellet was resuspended in 50 Al of kinase buffer,
along with 200 AM ATP, and 1 Ag ATF-2 fusion protein and
incubated at 30-C for 30 min. The reaction was terminated
with 50 Al of 3  SDS sample buffer [187.5 mM Tris–HCl
(pH 6.8 at 25-C), 6% w/v SDS, 30% glycerol, 150 mM
DTT, 0.03% w/v bromophenol blue]. The samples were
then boiled for 5 min and 30 Al was loaded on a 10% SDS-
PAGE gel, and transferred to nitrocellulose.
Fig. 2. Expression and activity of p38 MAP kinase in the 9.5 dpc mouse
somite. Upper panel shows the expression of p38 MAPK by Western
immunoblotting in muscle (M), brain (B), heart (H), somites vi–x (S vi–x),
somites (i–v), and in the unsegmented paraxial mesoderm (upm). Lower
panel shows p38 MAP kinase activity indicated by phosphorylation of a
bacterially produced ATF2 substrate by p38 MAPK immunoprecipitated
from the indicated tissues. UPM — unsegmented paraxial mesoderm, UPM
NT—UPM with neural tube, S i–v—somites i –v, SNT i–v—somites i–v
with neural tube, S vi–x—somites vi–x, SNT somites vi–x with neural
tube, C2 ANI—positive control of C2C12 myoblasts treated with
anisomycin (a known activator of p38 MAPK).
L. de Angelis et al. / Developmental Biology 283 (2005) 171–179174Results
Expression of MEF2A in the 9.5 dpc mouse embryo
We initially assessed the expression of MEF2 proteins in
transverse sections taken from the interlimb region of mouse
embryos using polyclonal antisera directed against the MEF2
factors. In Fig. 1, we present data representing the expression
of MEF2A in 9.5 dpc mouse embryos (Fig. 1, A3) in the
myotomal compartment as indicated by positive co-staining
with a sarcomeric myosin heavy chain directed antibody
(Fig. 1, A2). Temporally, we observed MEF2A protein
expression to precede positive myosin heavy chain staining
in the somite and MEF2A staining appeared concurrently
with Myf 5 protein expression at 9 dpc (data not shown). We
were unable to detect Myf 5 protein expression before 9 dpc,
although previous studies have documented expression at 8
dpc at the RNA level (Ott et al., 1991). This parallels the
observations of myogenin expression for which mRNAwas
detected at 8.5 dpc whereas the myogenin protein is not
detected until 10.5 dpc (Cusella-De Angelis et al., 1992).
Interestingly we also observed MEF2A staining in cells
aligning the neural tube (Fig. 1, A5 and A6) and in cells
surrounding the lining of dorsal vessels (Fig. 1, A6). TheFig. 1. Expression of MEF2 in the 9.5 dpc mouse embryo. (A1) Hoechst
staining of a transverse section at the V–X somite stage, D refers to dorsal,
V refers to ventral, NT refers to Neural Tube, and S refers to somite region.
The myotome is indicated by staining (red) with an anti-myosin heavy
chain antibody indicated in panel A2. Panel A3 indicates the expression of
MEF2A (green) in the embryonic myotome. Panels A4 and A5 show a
lower magnification of the same section indicating MEF2A-positive
staining (A5, green) in the myotome (M), cells surrounding the developing
vessels (V), and in neural crest precursor cells (NC) aligning the neural
tube. Panel A6 indicates a higher magnification of the MEF2A-positive NC
cells aligning the NT. Sections shown are representative of observations in
three independent experiments.other MEF2 factors (B, C, D) are expressed in complex
temporal and spatial patterns during embryogenesis but their
pattern of expression is not consistent with a role in early
myotomal myogenesis (data not shown).
Expression and activity of p38 MAP kinase in the 9.5 dpc
mouse somite
In order to determine if p38 MAPK is expressed and
active in the somitic regions of the developing embryo, we
performed Western blotting and immunoprecipitation kinase
assays as depicted in Fig. 2. This analysis was carried out by
immunoblotting rather than by staining sections because the
p38 antibody reagents do not work for immunocytochem-
istry on tissue sections. These data indicate that p38 MAPK
is expressed in the somites and unsegmented paraxial
mesoderm (top panel) and that this kinase is active as
indicated by the ability of immunoprecipitated p38 MAPK
from the indicated tissues to phosphorylate one of its
substrates (ATF2) shown in the lower panel. This activity
was not due to expression in the axial structures since
dissection with and without the neural tube region made no
difference (Fig. 2, lower panel).
p38 MAPK inhibition abrogates MEF2 activity in the MEF2
sensor mouse
In order to determine the role of p38 MAPK signaling for
MEF2 activity in the somite, we used the MEF2 sensor
mouse (Naya et al., 1999) which contains a MEF2-driven
reporter gene as an indicator of MEF2 activity (Fig. 3A).
From this mouse, we made somite explants and treated the
cultures with or without a cell-permeable p38 MAPK
inhibitor, SB203580 (SB), that has been extensively used
and characterized as a potent inhibitor of p38 MAPK a and
h isoforms. Incubation with an inactive analog of SB203580
Fig. 4. P38 MAPK inhibition blocks the induction of a myotomal myogenic
marker gene (MLC3F). The mouse picture indicates the expression of the
MLC3F LacZ transgene in the 9.5 dpc embryo (previously reported in
Kelly et al., 1995). Monolayer cultures derived from tissue dissected from
the interlimb region were incubated with the diluent (Control) or with the
SB203580 inhibitor for 3–5 days in culture and then stained with X gal
(representative data from 6 independent experiments). Panel B shows the
results of placental injection of the p38 MAPK inhibitor (SB203580). In
some cases, we observed the SB203580-injected embryos to be smaller
than the controls. We have normalized the size to allow details of the
embryo to be properly observed.
Fig. 3. A p38 MAPK inhibition abrogates MEF2 activity in the MEF2
sensor mouse. The mouse picture indicates the expression of the MEF2
LacZ transgene in the 9.5 dpc embryo (previously reported in Naya et al.,
1999). Explants dissected from the interlimb region were incubated with the
diluent (Control) or with the SB203580 inhibitor for 2 days and then stained
with X gal (representative data from 3 independent experiments). Panel B
shows representative data from a 48-h whole embryo incubation with or
without the p38 MAPK inhibitor (10 AM). This experiment was repeated
three times. H indicates the heart field, S indicates the somite region.
L. de Angelis et al. / Developmental Biology 283 (2005) 171–179 175(SB 203474) has no effect on MEF2 LacZ activity (data not
shown).
After 2 days in culture, the explants which continue to
differentiate under these conditions were stained with X gal
to observe MEF2 activity. The number of cells positive for
MEF2 activity was reduced by 41–63% (n = 3 independent
experiments) in the SB203580-treated somite explants (Fig.
3A). In addition, we performed whole embryo incubations
at 8.5–9 dpc for 48 h in the presence or absence of the
SB203580 inhibitor and we observed that MEF2 activity in
the cultured embryos was markedly reduced compared to
the controls in the somitic but not the heart field in the
SB203580-treated embryos (Fig. 3B). Interestingly, the
limbs are malformed in some of the SB203580-treated
embryos, although there were a range of phenotypes and
this was not evident in all treated embryos (n = 3
independent experiments) suggesting a possible role for
p38 MAPK signaling in limb development.p38 MAP kinase inhibition blocks myotomal myogenesis
Since MEF2 is an obligatory partner for the MRFs in the
myogenic program and previous reports have documented
that a dominant-negative inhibitor of MEF2 blocks the
differentiation of C2C12 myoblast in culture (Ornatsky et
al., 1997), we next determined if abrogation of p38 MAPK
signaling leads to a blockade of myotomal myogenesis. To
do this, we utilized a transgenic mouse harboring a reporter
gene driven by the myosin light chain 3F (MLC3F)
promoter which is a previously well-characterized marker
of myotomal myogenesis. We made monolayer (Fig. 4A) or
explant cultures (data not shown) from these mice and
treated them, as before, with or without SB203580. The
result was a marked diminution of differentiation, as
indicated by the reporter gene activity, in the SB-treated
cultures. In addition, we performed placental injections of
SB203580 at 8.5–9 dpc for 48 h and we observed that
MLC3F LacZ activity in the treated embryos was markedly
diminished compared to the controls in the somitic but not
Fig. 5. Activation of the Myf 5 locus is unaffected by P38 MAPK
inhibition. The mouse picture indicates the expression of the Myf 5nLacZ
transgene in the 9.5 dpc embryo (previously reported in Tajbakhsh et al.,
1996a). Explants dissected from the interlimb region were incubated with
the diluent (Control) or with the SB203580 inhibitor for 2 days and then
stained with X gal. Two independent experiments are indicated. Panel B
indicates the effect of incubating Myf 5 nLacZ somite cultures with the
inactive analog of SB203580 (SB203474). Panel C shows representative
results of placental injection of the p38 MAPK inhibitor on the expression
of the Myf 5nLacZ transgene.
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At this point, it is not possible to confirm that complete p38
MAPK inhibition was achieved in the embryos in the
transplacental injections of SB203580, although the pheno-
typic effects are considerable. Taken together, these data
indicate that p38 MAPK signaling is required for myotomal
myogenesis.
Induction of the Myf 5 locus is unaffected by p38 MAPK
inhibition
We next addressed the question of whether abrogation of
p38 MAPK signaling resulted in a loss of the myogenic
lineage in the somitic tissue. To do this, we used a
transgenic mouse in which a nuclear localized LacZ gene
has been knocked into the Myf 5 locus thus resulting in
expression of the LacZ gene when the Myf locus is activated
during embryogenesis (Tajbakhsh et al., 1996a). Since Myf
5 is one of the earliest known markers of commitment to the
myogenic lineage in the somite, we then used somite tissue
from this mouse to observe if p38 MAPK inhibition alters
the expression of the transgene and therefore commitment to
the myogenic lineage. These data are represented in Fig. 5A
and indicate that there is no difference in the activation of
the My5 nLacZ transgene with or without the p38 MAPK
inhibitor. In addition, we performed culture experiments
with the SB203474 analogue of SB203580 (Fig. 5B). This
analogue is structurally similar to SB203580 but does not
inhibit p38 MAPK activity. Therefore, it serves as a suitable
control for non-specific effects of the inhibitor. In these
experiments, we have not observed any effect of this
inactive SB analogue on any of the parameters measured
(Fig. 5B). Also, we performed intraplacental injections of
SB203580 at 8.5–9 dpc, and 48 h post-injection, we
observed that Myf 5 LacZ activity in the somites of the
treated embryos was normal or in some cases slightly
delayed compared to the controls (Fig. 5C). Therefore,
based on these explant and in vivo data, we conclude that
the commitment to the myogenic lineage is not appreciably
affected by inhibition of p38 MAPK signaling in the somite.
Co-localization of Myf 5 or myogenin expression with
MEF2 activity
Since we observed Myf 5 protein and MEF2A to be
approximately concurrently expressed in the somite (see
Fig. 1), we carried out further experiments co-localizing
MEF2 activity with Myf 5 or myogenin protein in 9–9.5
dpc somite cultures from MEF2 LacZ mice (Fig. 6). These
data indicate that in the majority of cases, Myf 5 expression
was localized with positive X gal staining for MEF2
activity. However, we did detect some cells that were Myf
5 positive but did not yet have MEF2 activity (Fig. 6A).
Conversely, we did not detect any cells that were MEF2
positive that did not have myogenin protein staining (Fig.
6B). Also, we observed that SB203580 treatment of somitecultures reduced the expression of myogenin (Fig. 6C)
consistent with the blockade of differentiation and the key
role played by MEF2 in the myogenin promoter (Cheng et
al., 1993; Yee and Rigby, 1993). Interestingly, if we make
explant cultures from the more rostral somites, p38 MAPK
inhibition does not affect myogenin expression, suggesting
that regulation of myogenin expression is not dependent on
p38 MAPK–MEF2 activity in this region. This observation
is consistent with the experiments reported by Yee and
Fig. 6. Co-localization of MEF2 LacZ activity with Myf 5 and myogenin.
Panel A shows the localization of MEF2 activity (left hand panel) with Myf
5 staining (right hand panel). Cells with arrows indicate Myf 5 positive cells
that are not positive for MEF2 activity (data is representative of two
independent experiments). Panel B shows the localization of MEF2 activity
(left hand panel) with myogenin staining (right-hand panel) (data are
representative of two independent experiments). Panel C indicates the effect
of SB203580 treatment on the expression of myogenin in confluent somite
cultures; in the control condition, the cells were incubated with an inactive
analogue of SB203580 (SB203474) at 10 AM.
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myogenin promoter did not affect the expression of
myogenin in all of the somitic muscle precursors. Thus,
our data indicate that Myf 5 protein expression transiently
precedes MEF2 activity by a narrow temporal window and
myogenin expression is concurrent with and likely preceded
by MEF2 expression and activity in the majority of somitic
muscle precursors.Discussion
In this report, we document a novel role for p38 MAPK
signaling to the MEF2 transcription factor in the developing
somite. Abrogation of this signaling pathway blocks
myogenic differentiation in the myotome, although it does
not influence commitment to the myogenic lineage. These
data thus identify p38 MAPK signaling as a crucial
determinant of myogenic differentiation in the early stages
of embryonic myotome development. Much attention has
been recently focused on the identification of signaling
molecules that commit and promote somitic mesodermal
cells into the myogenic lineage. Molecules such as Wnts,
Sonic hedgehog, BMP4, and noggin all contribute to somite
formation and differentiation (reviewed in Cossu et al.,2000; Tajbakhsh and Cossu, 1997). Thus, the linkage of
extracellular signals to the transcriptional machinery for
differentiation is beginning to be elucidated and will
constitute a major thrust for our understanding of somito-
genesis and general developmental programs. In this report,
we document a fundamental role for p38 MAPK signaling
to the MEF2 transcriptional regulators during somite
development. It will now be of significant interest to
determine which extracellular signals regulate p38 MAPK
activation in the developing somite.
Requirement for p38 signaling in the somite
The question of whether p38 MAPK signaling is
absolutely required for somite development is an important
one that has not been fully addressed as yet. Notably, a gene
targeting study on p38 MAPK a indicated robust activation
of a LacZ reporter gene in the somites of 10.5 dpc mouse
embryos when it was knocked into the p38 MAPK a locus
(Adams et al., 2000). However, even though the phenotype
of the homozygous null mutant (p38/) had severe
developmental defects including a drastic reduction in the
number of myocytes in the myocardium and severe growth
defects, these impairments were rescued when defects in the
placenta were rescued by aggregation of tetraploid (p38+/+)
and diploid (p38/) morula, suggesting that the primary
deficiency was due to compromised nutritional and oxygen
supply to the developing embryo (Adams et al., 2000).
Nevertheless, the robust activation of the p38 MAPK locus
in the developing somite (Adams et al., 2000), in agreement
with our data, suggests a potential role in the somite. An
important step in addressing this question using gene
targeting will be to breed combinatorial mutants of the
different p38 isoforms to address the absolute requirement
for p38 MAPK activity since the question of functional
redundancy is an important one as the p38 MAPK h isoform
is activated in a similar manner to p38 MAPK a, has similar
substrates, and both are inhibited by the SB203580
inhibitor. Since, the effects of p38 MAPK inhibition on
somitic myogenesis in our in vitro experiments are
independent of placental function and nutrient deprivation,
and both p38 MAPK a and h were inhibited, these data
suggest a primary requirement for p38 MAPK signaling for
somite myogenesis. It will be of great interest to analyze the
somitic tissue of p38 MAPK a and h (/) null embryos.
Differential regulation of MEF2 activity in the heart
compared to the somite?
Although we observed a large diminution of MEF2
activity when p38 MAPK signaling was blocked in the
somite, we saw little or no effect on the MEF2 activity in the
heart. Thus, these data point towards a different mechanism
of MEF2 regulation in the heart compared to in the somite
during early embryonic development. The reason for this
could be that p38 MAPK-independent signaling pathways
L. de Angelis et al. / Developmental Biology 283 (2005) 171–179178target MEF2 in the cardiac field. In fact, our recent studies,
and those of others, indicate that MEF2 is a recipient of
signals from several intracellular signaling cascades (Cox et
al., 2003; Kato et al., 1997; McKinsey et al., 2000, 2002;
Ornatsky et al., 1999; Yang et al., 1998; Youn et al., 1999).
Because of the clinical implications of the potential role of
MEF2 in cardiac hypertrophy, the signaling circuitry
controlling MEF2 activity in the developing heart is of
great interest and warrants thorough characterization.
p38 inhibition blocks the differentiation but not the
commitment to the myogenic lineage
A question that arose when we observed a lack of
expression of the myogenic MLC3F transgene in the somite
explants treated with the p38 inhibitor was whether this
treatment was converting the myogenic precursor cells to
another cell lineage. We addressed this question using a
transgenic mouse in which nuclear LacZ was knocked into
the Myf 5 locus. Since Myf 5 is the earliest definitive
marker of the myogenic lineage in the somite, this gave us a
sophisticated tool to address the question of lineage
commitment with p38 MAPK inhibition. In these experi-
ments, we observed that there was no effect of p38 MAPK
inhibition on the commitment to the myogenic lineage as
indicated by the activation of the Myf 5 locus. In addition,
placental injection of SB203580 had little or no effect on the
activation of the Myf nLacZ transgene even though it
drastically reduced MEF2 LacZ and MLC3F LacZ activity.
This result also obviated the possibility that p38 MAPK
signaling was playing a survival role and that the cells
committed to the myogenic lineage were dying because they
require p38 MAPK signaling for survival. However, p38
MAPK has a well-documented role in cell survival in other
cell types and MEF2 has also been implicated as a survival
factor in cerebellar granular neurons (Mao and Wiedmann,
1999; McKinsey et al., 2000). While we do not completely
rule out the possibility of a role for the p38 MAPK–MEF2
pathway as being important in cell survival in the somite,
our data to date do not support such a role.
These studies indicate a novel role for p38 MAPK
signaling in the development of the myotome compartment
within the vertebrate somite. The current genetic model
concerning the control of myogenesis by the MRF and
MEF2 families awaits accommodation of the kinase
cascades that regulate these transcriptional regulators.Acknowledgments
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